News | February 10, 2026
SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track
The company’s EBITDA margin remained resilient above 20%
The company’s EBITDA margin remained resilient above 20%
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
Jagsonpal Pharmaceuticals has reported total income of Rs. 75.92 crore during the period ended December 31, 2025
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Subscribe To Our Newsletter & Stay Updated
